Lee Phong Ching, Dixon John
Aust Fam Physician. 2017;46(7):472-477.
Obesity is a serious, chronic, relapsing disease of energy regulation, with strong genetic and early-life environmental determinants. Pharmacotherapy can be a useful adjunct to lifestyle intervention in effecting and maintaining clinically meaningful weight loss.
The aim of this article is to discuss the role of pharmacotherapy in obesity management. The efficacy, side effects and contraindications of available weight-loss medications are reviewed.
Long-term pharmacotherapy options, which can be effective in providing moderate weight loss, are available to treat obesity. Pharma-cotherapy should be considered an adjunct to lifestyle intervention in those with a body mass index (BMI) >30 kg/m30 kg/m2, or in those with a BMI of 27-30 kg/m2 and obesity-related complications. Safety and efficacy should be monitored closely on commencement, and the medication should be discontinued if there are safety or tolerability issues, or if.
肥胖是一种严重的、慢性的、复发性的能量调节疾病，具有强大的遗传和早期生活环境决定因素。药物治疗可作为生活方式干预的有益辅助手段，以实现并维持具有临床意义的体重减轻。
本文旨在探讨药物治疗在肥胖管理中的作用。对现有减肥药物的疗效、副作用和禁忌症进行综述。
有长期药物治疗方案可用于治疗肥胖，这些方案能有效实现适度体重减轻。对于体重指数（BMI）>30kg/m²的人群，或BMI为27 - 30kg/m²且伴有肥胖相关并发症的人群，药物治疗应被视为生活方式干预的辅助手段。开始治疗时应密切监测安全性和疗效，若出现安全或耐受性问题，或……则应停用药物。
